Teva loses plea against GSK’s $235m ‘skinny label’ win

The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Effects of GSK v Teva ripple after SCOTUS denies cert

23 May 2023 Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.

Big Pharma

GSK presses court to deny Teva’s ‘skinny label’ petition

25 August 2022 Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.

Americas

Teva takes long-running ‘skinny label’ suit to SCOTUS

14 July 2022 Generics giant’s petition cites the cost of medicine and first-principles of innovation.

More on this story

Big Pharma

Effects of GSK v Teva ripple after SCOTUS denies cert

Big Pharma

GSK presses court to deny Teva’s ‘skinny label’ petition

25 August 2022 Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.

Americas

Teva takes long-running ‘skinny label’ suit to SCOTUS

14 July 2022 Generics giant’s petition cites the cost of medicine and first-principles of innovation.

More on this story

Big Pharma

Effects of GSK v Teva ripple after SCOTUS denies cert

Big Pharma

GSK presses court to deny Teva’s ‘skinny label’ petition

25 August 2022 Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.

Americas

Teva takes long-running ‘skinny label’ suit to SCOTUS

14 July 2022 Generics giant’s petition cites the cost of medicine and first-principles of innovation.